Hotlist vs EU Annex II and III: Mapping the Overlap

If you're formulating for both Canada and the EU, you'll notice fast that the two lists rhyme a lot without being identical. Most ingredients that are prohibited in one market are prohibited in the other. But "most" is doing real work in that sentence, and the gaps are exactly where a maker who assumes the lists are interchangeable gets caught out.

What each list actually is

Canada's Cosmetic Ingredient Hotlist is a single reference document that names substances prohibited or restricted for use in cosmetics sold in Canada. It's maintained and updated by Health Canada and functions as the practical checklist behind the CNF filing process.

The EU's equivalent isn't one document, it's two, both attached to Regulation (EC) No 1223/2009:

• Annex II lists substances prohibited outright in cosmetic products.
• Annex III lists substances that are restricted, meaning they can be used but only under specific conditions like a maximum concentration, a required warning, or limits on which product types they can appear in.

Canada's Hotlist actually mirrors this same prohibited-versus-restricted split internally, it just presents both categories in one combined list rather than two separate annexes.

Where the two frameworks generally agree

For a large share of well-known problem ingredients, both systems land in roughly the same place. Substances with clear, long-established safety concerns, certain heavy metals, specific preservatives at unsafe levels, and a range of other substances with international consensus around their risk, tend to show up as prohibited or tightly restricted in both frameworks. If you're used to checking a formula against one list, you'll usually find the other list's treatment isn't a surprise for these well-established cases.

This overlap exists because both regulatory systems draw on overlapping scientific literature and, in many cases, similar international expert assessments. Neither one is inventing its risk assessments in isolation.

Where they diverge, and why that matters

The divergence tends to show up in a few predictable places:

• Timing. One market may restrict or prohibit a substance before the other does, simply because reviews and updates happen on independent schedules. A substance newly restricted in the EU might not yet appear on an updated Hotlist, and the reverse happens too.
• Concentration limits. Even when both lists restrict the same substance, the specific permitted concentration or the product categories it applies to can differ between the two.
• Category-specific conditions. Annex III entries often carry conditions tied to product type, leave-on versus rinse-off, or specific warning statement requirements, that don't necessarily map one-to-one onto how the Hotlist frames the same substance.
• Scope of what's covered. Some substances addressed under one framework simply haven't been addressed the same way under the other, particularly for newer or more niche ingredients.

A simplified way to think about it

Situation	What it means for you
Substance prohibited in both	No ambiguity, don't use it in either market
Substance restricted in both, same limit	Formulate to the stricter of the two if selling in both markets
Substance restricted in both, different limits	Formulate to whichever limit is lower if you want one formula for both markets
Substance addressed in one list but not clearly in the other	Don't assume silence means permission, check the other market's current guidance directly

That last row is the one that causes real problems. A maker checks the Hotlist, doesn't see their ingredient flagged, and assumes it's fine everywhere. But the Hotlist not flagging something tells you about Canada specifically. It says nothing about Annex II or III unless you've actually checked.

The practical takeaway if you sell into both markets

If you're formulating one product for sale in both Canada and the EU, the safest approach is checking both lists independently rather than assuming one covers the other, and formulating to whichever market's limit is more restrictive when the two disagree. It's more work upfront, but it means you're not reformulating or relabeling later when you expand into the second market.

This is also where the EU's separate structural requirements come in. Selling in the EU means notifying via the CPNP portal, appointing a Responsible Person established in the EU, and maintaining a Product Information File along with a Cosmetic Product Safety Report signed by a safety assessor, none of which have a direct Canadian equivalent in the CNF process. The ingredient list overlap is only part of the compliance picture.

Cosmetic Comply currently handles Canadian filings, screening formulas against the Hotlist with a confidence score and a real reviewer checking the result before a CN number comes back, with the US, EU, and Australia on the way. If your formula is destined for multiple markets right now, cross-checking Annex II and III directly against the EU's current published annexes is the right move until that broader coverage lands.